Brian Rini, MD, begins the conference with introductions and a warm welcome.
Tom Powles, MBBS, MRCP, MD, then begins the first bladder cancer panel session including Andrea Apolo, MD; Petros Grivas, MD, PhD; Shilpa Gupta, MD; and Kala Sridhar, MD, by discussing the addition of durvalumab to SOC in MIBC and its implications prompting practice change as well as other trials in the periop UC space.
Watch the second part of this panel: Adjuvant, Neoadjuvant Therapy and ctDNA Analysis in MIBC After NIAGARA Trial
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.